Pipeline

Looking to the Future of PWS Treatment

We are working hard to uncover new ways to treat Prader-Willi syndrome. Our research is informed by emerging developments in the understanding of PWS at the genetic level. We are following these paths in an effort to pave the way for a brighter future for both patients and caregivers.

LV-101 (Intranasal Carbetocin)

Our lead therapeutic program is LV-101 (intranasal carbetocin) for the treatment of hyperphagia and behavior associated with Prader-Willi syndrome.

A Phase 2 proof of concept study was conducted in 2014 testing LV-101 versus placebo in PWS.  This randomized, double-blinded, placebo-controlled study showed clinically meaningful improvements in hyperphagia and associated behavioral symptoms.  These data were recently presented at the 2018 Annual Meeting of the Pediatric Academic Societies and published in JCI Insight.

Based on the positive results seen in the Phase 2 study, Levo Therapeutics will be starting a Phase 3 clinical trial of LV-101 later in 2018.